<DOC>
	<DOCNO>NCT02366026</DOCNO>
	<brief_summary>The primary objective compare &amp; evaluate treatment group change decline/reduction HIV viral load change Remune + Amplivax group v Amplivax placebo group . Additional objective include change WBC White Blood Cell count &amp; CD4+ &amp; CD8+ T cell count along increase HIV immunity .</brief_summary>
	<brief_title>REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety &amp; Efficacy Study</brief_title>
	<detailed_description>This 500 subject Multi Center double-blind randomized , Safety &amp; Efficacy , HIV/AIDS Phase III study , primarily evaluate safety efficacy HIV-1 immunogen &amp; Amplivax compare placebo group Amplivax viral load , secondarily examine change CD4+ &amp; CD8+ T cell count , determine Remune vaccine effect multiple inoculation HIV-1 immunogen + Amplivax viral replication adult HIV-1 infection &amp; examine immunogenicity Remune + Amplivax Multi-center , randomize , double-blind , placebo-controlled , two arm parallel design study Remune + Amplivax .</detailed_description>
	<criteria>Are HIVpositive start antiHIV drug soon test show presence HIV . Are least 16 year old ( consent parent guardian require 18 year ) . Healthy Subjects Currently abuse alcohol drug .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
</DOC>